Understanding how immune diseases affect the nervous system

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the neurologic manifestations in patients with known or suspected primary and acquired errors of immunity. Researchers will conduct clinical evaluations, including neurologic exams and neuroimaging, and collect various biospecimens such as blood and cerebrospinal fluid for analysis. The study will also involve healthy biological relatives and volunteers as controls to better understand the interaction between the immune and nervous systems. The goal is to uncover the underlying mechanisms of neurologic diseases related to immune dysfunction.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Aged \>=2 years. To be seen at the NIH CC, participants must be \>=3 years of age.
2. Willing to allow specimens and data to be stored for future research.
3. Willing to allow genetic testing on their biospecimens.
4. Able to provide informed consent (for ages \>=18 years) or has parent(s) or guardian(s) who can provide permission to participate on their behalf (for ages \<18 years).

   * Decisionally impaired affected adult participants may have a legally authorized representative (LAR) to provide informed consent on their behalf.

Additional Inclusion Criterion for Affected Participants:

Has a primary or acquired immunodeficiency and known or suspected infection or inflammation of the nervous system or post-infection sequelae, based on clinical or imaging data provided by the referral facility, or is at risk of developing such a neurologic complication. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following:

1. Any neurologic symptoms accompanied by CSF with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation, including immunoglobulin \[Ig\] G index or presence of oligoclonal bands).
2. Systemic infection or inflammatory disease with neurologic involvement.
3. Neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI).
4. Clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation.
5. History of infection or inflammatory process of the nervous system.

Affected participants must also have their own primary health care provider to manage their condition outside the NIH.

Additional Inclusion Criteria for Biological Relatives and Healthy Volunteers:

1. Is either a biological relative of an affected participant or is unrelated.
2. Does not have a known diagnosis of neuroinfectious disease or neuroinflammation.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Pregnant (for biological relatives and healthy volunteers).
2. Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Farinaz Safavi, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
• Study coordinator: Kelsey L Yoo, P.A.-C
• Email: kelsey.yoo@nih.gov
• Phone: (240) 656-0596

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HL40626S tablets in healthy adults: a first-in-human dose study

  This Phase 1 study tests HL40626S tablets in healthy adults to see if it is safe, tolerated, and how it behaves in the body after single and 14-day multiple doses.

  Recruiting Phase 1 HighsLab Therapeutics Inc. · Melbourne, Victoria and 1 other locations · NCT07736586

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

• VLCPUFA-rich fish oil and standard DHA oil: who reaches a higher omega-3 index?

  This study tests whether VLCPUFA-rich fish oil raises the blood omega-3 index more than a standard DHA-rich fish oil in healthy adults aged 18–60.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07882160

• Blood biomarkers for immune-related neuropsychiatric conditions

  This study tests whether blood biomarkers can help identify neuropsychiatric disorders that may be linked to the immune system in people of any age.

  Recruiting at 3 sites National Institutes of Health Clinical Center (CC) · Los Angeles, California and 2 other locations · NCT07877246

• First-in-human imaging of PDE4D with [11C]JMJ-129-d2 in healthy volunteers

  A new PET tracer called [11C]JMJ-129-d2 is being tested in healthy adults to see if it safely and reliably images the brain’s PDE4D enzyme and to measure how the tracer distributes in the body.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07853781

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.